Confounding parameters in preclinical assessment of blood-brain barrier permeation: An overview with emphasis on species differences and effect of disease states

Molecular Pharmaceutics

Volumn 10, Issue 5, 2013, Pages 1581-1595

  Deo, Anand K ^a   Theil, Frank Peter ^a   Nicolas, Jean Marie ^a  

^a UCB PHARMA   (Belgium)

Author keywords

barrier integrity; blood cerebrospinal fluid barrier; blood brain barrier; CNS drugs; logBB; P glycoprotein; permeability; unbound drug concentration

Indexed keywords

ANTICONVULSIVE AGENT; FLUOXETINE; MULTIDRUG RESISTANCE PROTEIN; SUMATRIPTAN; ZIDOVUDINE; CENTRAL NERVOUS SYSTEM AGENTS;

BLOOD BRAIN BARRIER; BRAIN BLOOD FLOW; CENTRAL NERVOUS SYSTEM; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RECEPTOR BINDING; HUMAN; HYDROPHILICITY; IN VITRO STUDY; MEMBRANE PERMEABILITY; MIGRAINE; NEUROLOGIC DISEASE; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; BLOOD; CAPILLARY PERMEABILITY; CENTRAL NERVOUS SYSTEM DISEASES; METABOLISM; SPECIES DIFFERENCE;

ANIMALS; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CENTRAL NERVOUS SYSTEM AGENTS; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; SPECIES SPECIFICITY;

EID: 84875485383     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300570z     Document Type: Review

References (200)

1. Wolburg, H.; Paulus, W. Choroid plexus: biology and pathology Acta Neuropathol. 2010, 119 (1) 75-88
2. Dohrmann, G. J. The choroid plexus: a historical review Brain Res. 1970, 18 (2) 197-218
3. Ballabh, P.; Braun, A.; Nedergaard, M. The blood-brain barrier: an overview: structure, regulation, and clinical implications Neurobiol. Dis. 2004, 16 (1) 1-13
4. Pardridge, W. M. Drug and gene targeting to the brain with molecular Trojan horses Nat. Rev. Drug Discovery 2002, 1 (2) 131-9
5. Pardridge, W. M. The blood-brain barrier: bottleneck in brain drug development NeuroRx 2005, 2 (1) 3-14
6. Reichel, A. The role of blood-brain barrier studies in the pharmaceutical industry Curr. Drug Metab. 2006, 7 (2) 183-203
7. Pardridge, W. M. Log(BB), PS products and in silico models of drug brain penetration Drug Discovery Today 2004, 9 (9) 392-3
8. Liu, X.; Chen, C.; Smith, B. J. Progress in brain penetration evaluation in drug discovery and development J. Pharmacol. Exp. Ther. 2008, 325 (2) 349-56
9. Smith, Q. R. Brain perfusion systems for studies of drug uptake and metabolism in the central nervous system Pharm. Biotechnol. 1996, 8, 285-307
10. Fenstermacher, J. D. The blood-brain barrier is not a "barrier" for many drugs NIDA Res. Monogr. 1992, 120, 108-20
11. Abraham, M. H. The permeation of neutral molecules, ions, and ionic species through membranes: brain permeation as an example J. Pharm. Sci. 2011, 100 (5) 1690-701
12. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Use of a physiologically based pharmacokinetic model to study the time to reach brain equilibrium: an experimental analysis of the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding J. Pharmacol. Exp. Ther. 2005, 313 (3) 1254-62
13. Terasaki, T.; Ohtsuki, S.; Hori, S.; Takanaga, H.; Nakashima, E.; Hosoya, K. New approaches to in vitro models of blood-brain barrier drug transport Drug Discovery Today 2003, 8 (20) 944-54
14. Muehlbacher, M.; Spitzer, G. M.; Liedl, K. R.; Kornhuber, J. Qualitative prediction of blood-brain barrier permeability on a large and refined dataset J Comput.-Aided Mol. Des. 2011, 25 (12) 1095-106
15. Bickel, U. How to measure drug transport across the blood-brain barrier NeuroRx 2005, 2 (1) 15-26
16. Abraham, M. H.; Acree, W. E., Jr.; Leo, A. J.; Hoekman, D.; Cavanaugh, J. E. Water-solvent partition coefficients and Delta Log P values as predictors for blood-brain distribution; application of the Akaike information criterion J. Pharm. Sci. 2010, 99 (5) 2492-501
17. Abraham, M. H.; Ibrahim, A.; Zhao, Y.; Acree, W. E., Jr. A data base for partition of volatile organic compounds and drugs from blood/plasma/serum to brain, and an LFER analysis of the data J. Pharm. Sci. 2006, 95 (10) 2091-100
18. Luco, J. M. Prediction of the brain-blood distribution of a large set of drugs from structurally derived descriptors using partial least-squares (PLS) modeling J. Chem. Inf. Comput. Sci. 1999, 39 (2) 396-404
19. Zhao, Y. H.; Abraham, M. H.; Ibrahim, A.; Fish, P. V.; Cole, S.; Lewis, M. L. de Groot, M. J.; Reynolds, D. P. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes J. Chem. Inf. Modeling 2007, 47 (1) 170-5
20. Lombardo, F.; Blake, J. F.; Curatolo, W. J. Computation of brain-blood partitioning of organic solutes via free energy calculations J. Med. Chem. 1996, 39 (24) 4750-5
21. Pajouhesh, H.; Lenz, G. R. Medicinal chemical properties of successful central nervous system drugs NeuroRx 2005, 2 (4) 541-53
22. Maurer, T. S.; Debartolo, D. B.; Tess, D. A.; Scott, D. O. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice Drug Metab. Dispos. 2005, 33 (1) 175-81
23. Boriss, H. Brain Availability Is the Key Parameter for Optimising the Permeability of Central Nervous System Drugs Drug Discovery 2010, 7, 57-60
24. Summerfield, S. G.; Stevens, A. J.; Cutler, L.; del Carmen Osuna, M.; Hammond, B.; Tang, S. P.; Hersey, A.; Spalding, D. J.; Jeffrey, P. Improving the in vitro prediction of in vivo central nervous system penetration: integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain J. Pharmacol. Exp. Ther. 2006, 316 (3) 1282-90
25. Liu, X.; Smith, B. J.; Chen, C.; Callegari, E.; Becker, S. L.; Chen, X.; Cianfrogna, J.; Doran, A. C.; Doran, S. D.; Gibbs, J. P.; Hosea, N.; Liu, J.; Nelson, F. R.; Szewc, M. A.; Van Deusen, J. Evaluation of cerebrospinal fluid concentration and plasma free concentration as a surrogate measurement for brain free concentration Drug Metab. Dispos. 2006, 34 (9) 1443-7
26. Kalvass, J. C.; Maurer, T. S.; Pollack, G. M. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: comparison of unbound concentration ratios to in vivo p-glycoprotein efflux ratios Drug Metab. Dispos. 2007, 35 (4) 660-6
27. Tfelt-Hansen, P. C. Does Sumatriptan cross the blood-brain barrier in animals and man? J. Headache Pain 2010, 11 (1) 5-12
28. Doran, A.; Obach, R. S.; Smith, B. J.; Hosea, N. A.; Becker, S.; Callegari, E.; Chen, C.; Chen, X.; Choo, E.; Cianfrogna, J.; Cox, L. M.; Gibbs, J. P.; Gibbs, M. A.; Hatch, H.; Hop, C. E.; Kasman, I. N.; Laperle, J.; Liu, J.; Liu, X.; Logman, M.; Maclin, D.; Nedza, F. M.; Nelson, F.; Olson, E.; Rahematpura, S.; Raunig, D.; Rogers, S.; Schmidt, K.; Spracklin, D. K.; Szewc, M.; Troutman, M.; Tseng, E.; Tu, M.; Van Deusen, J. W.; Venkatakrishnan, K.; Walens, G.; Wang, E. Q.; Wong, D.; Yasgar, A. S.; Zhang, C. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model Drug Metab. Dispos. 2005, 33 (1) 165-74
29. van de Waterbeemd, H.; Smith, D. A.; Jones, B. C. Lipophilicity in PK design: methyl, ethyl, futile J. Comput.-Aided Mol. Des. 2001, 15 (3) 273-86
30. Martin, I. Prediction of blood-brain barrier penetration: are we missing the point? Drug Discovery Today 2004, 9 (4) 161-2
31. Westerhout, J.; Danhof, M.; De Lange, E. C. Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting J. Pharm. Sci. 2011, 100 (9) 3577-93
32. Wu, D.; Clement, J. G.; Pardridge, W. M. Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat Brain Res. 1998, 791 (1-2) 313-6
33. Di, L.; Rong, H.; Feng, B. Demystifying Brain Penetration in Central Nervous System Drug Discovery J. Med. Chem. 2012, 10.1021/jm301297f
34. Westerhout, J.; Ploeger, B.; Smeets, J.; Danhof, M.; de Lange, E. C. Physiologically based pharmacokinetic modeling to investigate regional brain distribution kinetics in rats AAPS J. 2012, 14 (3) 543-53
35. Ball, K.; Bouzom, F.; Scherrmann, J. M.; Walther, B.; Decleves, X. Development of a physiologically based pharmacokinetic model for the rat central nervous system and determination of an in vitro-in vivo scaling methodology for the blood-brain barrier permeability of two transporter substrates, morphine and oxycodone J. Pharm. Sci. 2012, 101 (11) 4277-92
36. Schroeter, J. D.; Dorman, D. C.; Yoon, M.; Nong, A.; Taylor, M. D.; Andersen, M. E.; Clewell, H. J., 3rd. Application of a multi-route physiologically based pharmacokinetic model for manganese to evaluate dose-dependent neurological effects in monkeys Toxicol. Sci. 2012, 129 (2) 432-46
37. Liu, X.; Van Natta, K.; Yeo, H.; Vilenski, O.; Weller, P. E.; Worboys, P. D.; Monshouwer, M. Unbound drug concentration in brain homogenate and cerebral spinal fluid at steady state as a surrogate for unbound concentration in brain interstitial fluid Drug Metab. Dispos. 2009, 37 (4) 787-93
38. Eyal, S.; Ke, B.; Muzi, M.; Link, J. M.; Mankoff, D. A.; Collier, A. C.; Unadkat, J. D. Regional P-glycoprotein activity and inhibition at the human blood-brain barrier as imaged by positron emission tomography Clin. Pharmacol. Ther. 2010, 87 (5) 579-85
39. Stange, K.; Greitz, D.; Ingvar, M.; Hindmarsh, T.; Sollevi, A. Global cerebral blood flow during infusion of adenosine in humans: assessment by magnetic resonance imaging and positron emission tomography Acta Physiol. Scand. 1997, 160 (2) 117-22
40. Maurer, M. H. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) Mass Spectrom. Rev. 2010, 29 (1) 17-28
41. Johanson, C. E.; Duncan, J. A., 3rd; Klinge, P. M.; Brinker, T.; Stopa, E. G.; Silverberg, G. D. Multiplicity of cerebrospinal fluid functions: New challenges in health and disease Cerebrospinal Fluid Res. 2008, 5, 10
42. Peyret, T.; Poulin, P.; Krishnan, K. A unified algorithm for predicting partition coefficients for PBPK modeling of drugs and environmental chemicals Toxicol. Applied Pharmacol. 2010, 249 (3) 197-207
43. Rodgers, T.; Jones, H. M.; Rowland, M. Tissue lipids and drug distribution: Dog versus rat J. Pharm. Sci. 2012, 101 (12) 4615-26
44. Poulin, P.; Theil, F. P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution J. Pharm. Sci. 2002, 91 (1) 129-56
45. Rodgers, T.; Leahy, D.; Rowland, M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 2005, 94 (6) 1259-76
46. Giacomini, K. M.; Huang, S. M.; Tweedie, D. J.; Benet, L. Z.; Brouwer, K. L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K. M.; Hoffmaster, K. A.; Ishikawa, T.; Keppler, D.; Kim, R. B.; Lee, C. A.; Niemi, M.; Polli, J. W.; Sugiyama, Y.; Swaan, P. W.; Ware, J. A.; Wright, S. H.; Yee, S. W.; Zamek-Gliszczynski, M. J.; Zhang, L. Membrane transporters in drug development Nat. Rev. Drug Discovery 2010, 9 (3) 215-36
47. Eyal, S.; Hsiao, P.; Unadkat, J. D. Drug interactions at the blood-brain barrier: Fact or fantasy? Pharmacol. Ther. 2009, 123 (1) 80-104
48. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding Science 2009, 323 (5922) 1718-22
49. Lee, C. A.; Cook, J. A.; Reyner, E. L.; Smith, D. A. P-glycoprotein related drug interactions: clinical importance and a consideration of disease states Expert Opin. Drug Metab. Toxicol. 2010, 6 (5) 603-19
50. Kamiie, J.; Ohtsuki, S.; Iwase, R.; Ohmine, K.; Katsukura, Y.; Yanai, K.; Sekine, Y.; Uchida, Y.; Ito, S.; Terasaki, T. Quantitative atlas of membrane transporter proteins: development and application of a highly sensitive simultaneous LC/MS/MS method combined with novel in-silico peptide selection criteria Pharm. Res. 2008, 25 (6) 1469-83
51. Uchida, Y.; Ohtsuki, S.; Katsukura, Y.; Ikeda, C.; Suzuki, T.; Kamiie, J.; Terasaki, T. Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J. Neurochem. 2011, 117 (2) 333-45
52. Ito, K.; Uchida, Y.; Ohtsuki, S.; Aizawa, S.; Kawakami, H.; Katsukura, Y.; Kamiie, J.; Terasaki, T. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys J. Pharm. Sci. 2011, 100 (9) 3939-50
53. Agarwal, S.; Uchida, Y.; Mittapalli, R. K.; Sane, R.; Terasaki, T.; Elmquist, W. F. Quantitative proteomics of transporter expression in brain capillary endothelial cells isolated from P-glycoprotein (P-gp), breast cancer resistance protein (Bcrp), and P-gp/Bcrp knockout mice Drug Metab. Dispos. 2012, 40 (6) 1164-9
54. Shawahna, R.; Uchida, Y.; Decleves, X.; Ohtsuki, S.; Yousif, S.; Dauchy, S.; Jacob, A.; Chassoux, F.; Daumas-Duport, C.; Couraud, P. O.; Terasaki, T.; Scherrmann, J. M. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels Mol. Pharmaceutics 2011, 8 (4) 1332-41
55. Dauchy, S.; Dutheil, F.; Weaver, R. J.; Chassoux, F.; Daumas-Duport, C.; Couraud, P. O.; Scherrmann, J. M.; De Waziers, I.; Decleves, X. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier J. Neurochem. 2008, 107 (6) 1518-28
56. Booth-Genthe, C. L.; Louie, S. W.; Carlini, E. J.; Li, B.; Leake, B. F.; Eisenhandler, R.; Hochman, J. H.; Mei, Q.; Kim, R. B.; Rushmore, T. H.; Yamazaki, M. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse J. Pharmacol. Toxicol. Methods 2006, 54 (1) 78-89
57. Katoh, M.; Suzuyama, N.; Takeuchi, T.; Yoshitomi, S.; Asahi, S.; Yokoi, T. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport J. Pharm. Sci. 2006, 95 (12) 2673-83
58. Takeuchi, T.; Yoshitomi, S.; Higuchi, T.; Ikemoto, K.; Niwa, S.; Ebihara, T.; Katoh, M.; Yokoi, T.; Asahi, S. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1 Pharm. Res. 2006, 23 (7) 1460-72
59. Ohe, T.; Sato, M.; Tanaka, S.; Fujino, N.; Hata, M.; Shibata, Y.; Kanatani, A.; Fukami, T.; Yamazaki, M.; Chiba, M.; Ishii, Y. Effect of P-glycoprotein-mediated efflux on cerebrospinal fluid/plasma concentration ratio Drug Metab. Dispos. 2003, 31 (10) 1251-4
60. Baltes, S.; Gastens, A. M.; Fedrowitz, M.; Potschka, H.; Kaever, V.; Loscher, W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein Neuropharmacology 2007, 52 (2) 333-46
61. Suzuyama, N.; Katoh, M.; Takeuchi, T.; Yoshitomi, S.; Higuchi, T.; Asashi, S.; Yokoi, T. Species differences of inhibitory effects on P-glycoprotein-mediated drug transport J. Pharm. Sci. 2007, 96 (6) 1609-18
62. Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Morais, S. M. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos. 2008, 36 (2) 268-75
63. Syvanen, S.; Lindhe, O.; Palner, M.; Kornum, B. R.; Rahman, O.; Langstrom, B.; Knudsen, G. M.; Hammarlund-Udenaes, M. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab. Dispos. 2009, 37 (3) 635-43
64. Liow, J. S.; Lu, S.; McCarron, J. A.; Hong, J.; Musachio, J. L.; Pike, V. W.; Innis, R. B.; Zoghbi, S. S. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY Synapse 2007, 61 (2) 96-105
65. Pike, V. W.; McCarron, J. A.; Lammertsma, A. A.; Osman, S.; Hume, S. P.; Sargent, P. A.; Bench, C. J.; Cliffe, I. A.; Fletcher, A.; Grasby, P. M. Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635 Eur. J. Pharmacol. 1996, 301 (1-3) R5-7
66. Yasuno, F.; Zoghbi, S. S.; McCarron, J. A.; Hong, J.; Ichise, M.; Brown, A. K.; Gladding, R. L.; Bacher, J. D.; Pike, V. W.; Innis, R. B. Quantification of serotonin 5-HT1A receptors in monkey brain with [11C](R)-(-)-RWAY Synapse 2006, 60 (7) 510-20
67. Hsiao, P.; Sasongko, L.; Link, J. M.; Mankoff, D. A.; Muzi, M.; Collier, A. C.; Unadkat, J. D. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data J. Pharmacol. Exp. Ther. 2006, 317 (2) 704-10
68. Xia, C. Q.; Xiao, G.; Liu, N.; Pimprale, S.; Fox, L.; Patten, C. J.; Crespi, C. L.; Miwa, G.; Gan, L. S. Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays Mol. Pharmaceutics 2006, 3 (1) 78-86
69. Pauli-Magnus, C.; von Richter, O.; Burk, O.; Ziegler, A.; Mettang, T.; Eichelbaum, M.; Fromm, M. F. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein J. Pharmacol. Exp. Ther. 2000, 293 (2) 376-82
70. Syvanen, S.; Hooker, A.; Rahman, O.; Wilking, H.; Blomquist, G.; Langstrom, B.; Bergstrom, M.; Hammarlund-Udenaes, M. Pharmacokinetics of P-glycoprotein inhibition in the rat blood-brain barrier J. Pharm. Sci. 2008, 97 (12) 5386-400
71. Choi, T. B.; Pardridge, W. M. Phenylalanine transport at the human blood-brain barrier. Studies with isolated human brain capillaries J. Biol. Chem. 1986, 261 (14) 6536-41
72. Gruetter, R.; Novotny, E. J.; Boulware, S. D.; Rothman, D. L.; Shulman, R. G. 1H NMR studies of glucose transport in the human brain J. Cereb. Blood Flow Metab. 1996, 16 (3) 427-38
73. Pardridge, W. M. Brain metabolism: a perspective from the blood-brain barrier Physiol. Rev. 1983, 63 (4) 1481-535
74. Ferguson, C. S.; Tyndale, R. F. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance Trends Pharmacol. Sci. 2011, 32 (12) 708-14
75. Minn, A.; Ghersi-Egea, J. F.; Perrin, R.; Leininger, B.; Siest, G. Drug metabolizing enzymes in the brain and cerebral microvessels Brain Res. Rev. 1991, 16 (1) 65-82
76. Ghersi-Egea, J. F.; Leninger-Muller, B.; Suleman, G.; Siest, G.; Minn, A. Localization of drug-metabolizing enzyme activities to blood-brain interfaces and circumventricular organs J. Neurochem. 1994, 62 (3) 1089-96
77. Richard, K.; Hume, R.; Kaptein, E.; Stanley, E. L.; Visser, T. J.; Coughtrie, M. W. Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung, and brain J. Clin. Endocrinol. Metab. 2001, 86 (6) 2734-42
78. Cammer, W.; Tansey, F.; Abramovitz, M.; Ishigaki, S.; Listowsky, I. Differential localization of glutathione-S-transferase Yp and Yb subunits in oligodendrocytes and astrocytes of rat brain J. Neurochem. 1989, 52 (3) 876-83
79. Lindvall, M.; Hardebo, J. E.; Owman, C. Barrier mechanisms for neutrotransmitter monoamines in the choroid plexus Acta Physiol. Scand. 1980, 108 (3) 215-21
80. Lamb, D. C.; Waterman, M. R.; Kelly, S. L.; Guengerich, F. P. Cytochromes P450 and drug discovery Curr. Opin. Biotechnol. 2007, 18 (6) 504-12
81. Murakami, H.; Takanaga, H.; Matsuo, H.; Ohtani, H.; Sawada, Y. Comparison of blood-brain barrier permeability in mice and rats using in situ brain perfusion technique Am. J. Physiol. 2000, 279 (3) H1022-8
82. Ose, A.; Ito, M.; Kusuhara, H.; Yamatsugu, K.; Kanai, M.; Shibasaki, M.; Hosokawa, M.; Schuetz, J. D.; Sugiyama, Y. Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4) Drug Metab. Dispos. 2009, 37 (2) 315-21
83. Toovey, S.; Rayner, C.; Prinssen, E.; Chu, T.; Donner, B.; Thakrar, B.; Dutkowski, R.; Hoffmann, G.; Breidenbach, A.; Lindemann, L.; Carey, E.; Boak, L.; Gieschke, R.; Sacks, S.; Solsky, J.; Small, I.; Reddy, D. Assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: a comprehensive review Drug Saf. 2008, 31 (12) 1097-114
84. Edwards, G. Ivermectin: does P-glycoprotein play a role in neurotoxicity? Filaria J. 2003, 2 (Suppl. 1) S8
85. Zlokovic, B. V. The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 2008, 57 (2) 178-201
86. Vangilder, R. L.; Rosen, C. L.; Barr, T. L.; Huber, J. D. Targeting the neurovascular unit for treatment of neurological disorders Pharmacol. Ther. 2011, 130 (3) 239-47
87. Popescu, B. O.; Toescu, E. C.; Popescu, L. M.; Bajenaru, O.; Muresanu, D. F.; Schultzberg, M.; Bogdanovic, N. Blood-brain barrier alterations in ageing and dementia J. Neurol. Sci. 2009, 283 (1-2) 99-106
88. del Zoppo, G. J.; Poeck, K.; Pessin, M. S.; Wolpert, S. M.; Furlan, A. J.; Ferbert, A.; Alberts, M. J.; Zivin, J. A.; Wechsler, L.; Busse, O. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke Ann. Neurol. 1992, 32 (1) 78-86
89. Paul, R.; Lorenzl, S.; Koedel, U.; Sporer, B.; Vogel, U.; Frosch, M.; Pfister, H. W. Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis Ann. Neurol. 1998, 44 (4) 592-600
90. Wolka, A. M.; Huber, J. D.; Davis, T. P. Pain and the blood-brain barrier: obstacles to drug delivery Adv. Drug Delivery Rev. 2003, 55 (8) 987-1006
91. Nishioku, T.; Furusho, K.; Tomita, A.; Ohishi, H.; Dohgu, S.; Shuto, H.; Yamauchi, A.; Kataoka, Y. Potential role for S100A4 in the disruption of the blood-brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis Neuroscience 2011, 189, 286-92
92. Starr, J. M.; Wardlaw, J.; Ferguson, K.; MacLullich, A.; Deary, I. J.; Marshall, I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging J. Neurol., Neurosurg. Psychiatry 2003, 74 (1) 70-6
93. Nguyen, J. H. Blood-brain barrier in acute liver failure Neurochem. Int. 2012, 60 (7) 676-83
94. Cipolla, M. J.; Sweet, J. G.; Chan, S. L. Cerebral vascular adaptation to pregnancy and its role in the neurological complications of eclampsia J. Appl. Physiol. 2011, 110 (2) 329-39
95. Tang, J. P.; Rakhit, A.; Douglas, F. L.; Melethil, S. Effect of chronic hypertension on the blood-brain barrier permeability of libenzapril Pharm. Res. 1992, 9 (2) 236-43
96. Ong, W. Y.; Halliwell, B. Iron, atherosclerosis, and neurodegeneration: a key role for cholesterol in promoting iron-dependent oxidative damage? Ann. N.Y. Acad. Sci. 2004, 1012, 51-64
97. Ogunshola, O. O.; Al-Ahmad, A. HIF-1 at the blood-brain barrier: a mediator of permeability? High Alt. Med. Biol. 2012, 13 (3) 153-61
98. Bowman, G. L.; Kaye, J. A.; Moore, M.; Waichunas, D.; Carlson, N. E.; Quinn, J. F. Blood-brain barrier impairment in Alzheimer disease: stability and functional significance Neurology 2007, 68 (21) 1809-14
99. Pisani, V.; Stefani, A.; Pierantozzi, M.; Natoli, S.; Stanzione, P.; Franciotta, D.; Pisani, A. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease J. Neuroinflammation 2012, 9 (1) 188
100. van Assema, D. M.; Lubberink, M.; Bauer, M.; van der Flier, W. M.; Schuit, R. C.; Windhorst, A. D.; Comans, E. F.; Hoetjes, N. J.; Tolboom, N.; Langer, O.; Muller, M.; Scheltens, P.; Lammertsma, A. A.; van Berckel, B. N. Blood-brain barrier P-glycoprotein function in Alzheimer's disease Brain 2012, 135 (Part 1) 181-9
101. Rapposelli, S.; Digiacomo, M.; Balsamo, A. P-gp transporter and its role in neurodegenerative diseases Curr. Top. Med. Chem. 2009, 9 (2) 209-17
102. Vogelgesang, S.; Glatzel, M.; Walker, L. C.; Kroemer, H. K.; Aguzzi, A.; Warzok, R. W. Cerebrovascular P-glycoprotein expression is decreased in Creutzfeldt-Jakob disease Acta Neuropathol. 2006, 111 (5) 436-43
103. Tishler, D. M.; Weinberg, K. I.; Hinton, D. R.; Barbaro, N.; Annett, G. M.; Raffel, C. MDR1 gene expression in brain of patients with medically intractable epilepsy Epilepsia 1995, 36 (1) 1-6
104. Hartz, A. M.; Notenboom, S.; Bauer, B. Signaling to P-glycoprotein-A new therapeutic target to treat drug-resistant epilepsy? Drug News Perspect. 2009, 22 (7) 393-7
105. Kooij, G.; van Horssen, J.; Bandaru, V. V.; Haughey, N. J.; de Vries, H. E. The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids Front. Pharmacol 2012, 3, 74
106. Kooij, G.; van Horssen, J.; Bandaru, V. V.; Haughey, N. J.; de Vries, H. E. The Role of ATP-Binding Cassette Transporters in Neuro-Inflammation: Relevance for Bioactive Lipids Front. Pharmacol. 2012, 3, 74
107. Kooij, G.; Backer, R.; Koning, J. J.; Reijerkerk, A.; van Horssen, J.; van der Pol, S. M.; Drexhage, J.; Schinkel, A.; Dijkstra, C. D.; den Haan, J. M.; Geijtenbeek, T. B.; de Vries, H. E. P-glycoprotein acts as an immunomodulator during neuroinflammation PLoS One 2009, 4 (12) e8212
108. Langford, D.; Grigorian, A.; Hurford, R.; Adame, A.; Ellis, R. J.; Hansen, L.; Masliah, E. Altered P-glycoprotein expression in AIDS patients with HIV encephalitis J. Neuropathol. Exp. Neurol. 2004, 63 (10) 1038-47
109. Aronica, E.; Sisodiya, S. M.; Gorter, J. A. Cerebral expression of drug transporters in epilepsy Adv. Drug Delivery Rev. 2012, 64 (10) 919-29
110. Donahue, J. E.; Flaherty, S. L.; Johanson, C. E.; Duncan, J. A., 3rd; Silverberg, G. D.; Miller, M. C.; Tavares, R.; Yang, W.; Wu, Q.; Sabo, E.; Hovanesian, V.; Stopa, E. G. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease Acta Neuropathol. 2006, 112 (4) 405-15
111. van Vliet, E. A.; Redeker, S.; Aronica, E.; Edelbroek, P. M.; Gorter, J. A. Expression of multidrug transporters MRP1, MRP2, and BCRP shortly after status epilepticus, during the latent period, and in chronic epileptic rats Epilepsia 2005, 46 (10) 1569-80
112. Kooij, G.; Mizee, M. R.; van Horssen, J.; Reijerkerk, A.; Witte, M. E.; Drexhage, J. A.; van der Pol, S. M.; van Het Hof, B.; Scheffer, G.; Scheper, R.; Dijkstra, C. D.; van der Valk, P.; de Vries, H. E. Adenosine triphosphate-binding cassette transporters mediate chemokine (C-C motif) ligand 2 secretion from reactive astrocytes: relevance to multiple sclerosis pathogenesis Brain 2011, 134 (Part 2) 555-70
113. Farrall, A. J.; Wardlaw, J. M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis Neurobiol. Aging 2009, 30 (3) 337-52
114. Watson, P.; Shirreffs, S. M.; Maughan, R. J. Blood-brain barrier integrity may be threatened by exercise in a warm environment Am. J. Physiol. 2005, 288 (6) R1689-94
115. Stanimirovic, D. B.; Friedman, A. Pathophysiology of the neurovascular unit: disease cause or consequence? J. Cereb. Blood Flow Metab. 2012, 32 (7) 1207-21
116. Spellerberg, B.; Prasad, S.; Cabellos, C.; Burroughs, M.; Cahill, P.; Tuomanen, E. Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides J. Exp. Med. 1995, 182 (4) 1037-43
117. Spector, R.; Lorenzo, A. V. Inhibition of penicillin transport from the cerebrospinal fluid after intracisternal inoculation of bacteria J. Clin. Invest. 1974, 54 (2) 316-25
118. Rodvold, K. A.; Gotfried, M. H.; Cwik, M.; Korth-Bradley, J. M.; Dukart, G.; Ellis-Grosse, E. J. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose J. Antimicrob. Chemother. 2006, 58 (6) 1221-9
119. Tutuncu, E. E.; Kuscu, F.; Gurbuz, Y.; Ozturk, B.; Haykir, A.; Sencan, I. Tigecycline use in two cases with multidrug-resistant Acinetobacter baumannii meningitis Int. J. Infect. Dis. 2010, 14 (Suppl. 3) e224-6
120. Lengerke, C.; Haap, M.; Mayer, F.; Kanz, L.; Kinzig, M.; Schumacher, U.; Sorgel, F.; Riessen, R. Low tigecycline concentrations in the cerebrospinal fluid of a neutropenic patient with inflamed meninges Antimicrob. Agents Chemother. 2011, 55 (1) 449-50
121. Vautier, S.; Fernandez, C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs Expert Opin. Drug Metab. Toxicol. 2009, 5 (11) 1349-58
122. Potschka, H. Modulating P-glycoprotein regulation: future perspectives for pharmacoresistant epilepsies? Epilepsia 2010, 51 (8) 1333-47
123. Marchi, N.; Betto, G.; Fazio, V.; Fan, Q.; Ghosh, C.; Machado, A.; Janigro, D. Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema Epilepsia 2009, 50 (4) 664-77
124. Loscher, W.; Luna-Tortos, C.; Romermann, K.; Fedrowitz, M. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected Curr. Pharm. Des. 2011, 17 (26) 2808-28
125. Takeda, T.; Hosokawa, M.; Takeshita, S.; Irino, M.; Higuchi, K.; Matsushita, T.; Tomita, Y.; Yasuhira, K.; Hamamoto, H.; Shimizu, K.; Ishii, M.; Yamamuro, T. A new murine model of accelerated senescence Mech. Ageing Dev. 1981, 17 (2) 183-94
126. Morley, J. E.; Farr, S. A.; Kumar, V. B.; Armbrecht, H. J. The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease Curr. Pharm. Des. 2012, 18 (8) 1123-30
127. Kondziella, D.; Hammer, J.; Sletvold, O.; Sonnewald, U. The pentylenetetrazole-kindling model of epilepsy in SAMP8 mice: glial-neuronal metabolic interactions Neurochem. Int. 2003, 43 (7) 629-37
128. Liu, J.; Wang, Y. Y.; Liu, L.; Wang, Q. D.; Yuan, Z. Y.; Zhang, Z. X.; Gu, P.; Wang, M. W. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse Neurosci. Lett. 2008, 448 (2) 184-8
129. Lee, V. K.; Tiwary, A. K.; Sharma-Reddy, P.; Lieber, K. A.; Taylor, D. K.; Mook, D. M. Moxidectin toxicity in senescence-accelerated prone and resistant mice Comp. Med. 2009, 59 (3) 227-33
130. Uchida, S.; Yamada, S.; Deguchi, Y.; Yamamoto, M.; Kimura, R. In vivo specific binding characteristics and pharmacokinetics of a 1,4-dihydropyridine calcium channel antagonist in the senescent mouse brain Pharm. Res. 2000, 17 (7) 844-50
131. Banks, W. A.; Moinuddin, A.; Morley, J. E. Regional transport of TNF-alpha across the blood-brain barrier in young ICR and young and aged SAMP8 mice Neurobiol. Aging 2001, 22 (4) 671-6
132. Dawson, G. R.; Dourish, C. T.; Goodwin, G. M. Special issue on CNS experimental medicine J. Psychopharmacol. 2011, 25 (9) 1145-7
133. Palmer, A. M.; Alavijeh, M. S. Translational CNS medicines research Drug Discovery Today 2012, 17 (19-20) 1068-78
134. Jeffrey, P.; Summerfield, S. G. Challenges for blood-brain barrier (BBB) screening Xenobiotica 2007, 37 (10-11) 1135-51
135. Reichel, A. Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept Chem. Biodiversity 2009, 6 (11) 2030-49
136. Kerns, E. H.; Di, L. Drug-like Properties: Concepts, Structure Design and Methods: from ADME to Toxicity Optimization. Academic Press: London, U.K., 2008.
137. Jahnke, K.; Muldoon, L. L.; Varallyay, C. G.; Lewin, S. J.; Brown, R. D.; Kraemer, D. F.; Soussain, C.; Neuwelt, E. A. Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma Neuro-Oncology 2009, 11 (5) 503-13
138. Doolittle, N. D.; Jahnke, K.; Belanger, R.; Ryan, D. A.; Nance, R. W., Jr.; Lacy, C. A.; Tyson, R. M.; Haluska, M.; Hedrick, N. A.; Varallyay, C.; Neuwelt, E. A. Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma Leuk. Lymphoma 2007, 48 (9) 1712-20
139. Morsing, P.; Adler, G.; Brandt-Eliasson, U.; Karp, L.; Ohlson, K.; Renberg, L.; Sjoquist, P. O.; Abrahamsson, T. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin Hypertension 1999, 33 (6) 1406-13
140. Hajjar, I.; Brown, L.; Mack, W. J.; Chui, H. Impact of Angiotensin Receptor Blockers on Alzheimer Disease Neuropathology in a Large Brain Autopsy Series Arch. Neurol. 2012, 1-7
141. Pelisch, N.; Hosomi, N.; Ueno, M.; Masugata, H.; Murao, K.; Hitomi, H.; Nakano, D.; Kobori, H.; Nishiyama, A.; Kohno, M. Systemic candesartan reduces brain angiotensin II via downregulation of brain renin-angiotensin system Hypertens. Res. 2010, 33 (2) 161-4
142. Corbett, A.; Pickett, J.; Burns, A.; Corcoran, J.; Dunnett, S. B.; Edison, P.; Hagan, J. J.; Holmes, C.; Jones, E.; Katona, C.; Kearns, I.; Kehoe, P.; Mudher, A.; Passmore, A.; Shepherd, N.; Walsh, F.; Ballard, C. Drug repositioning for Alzheimer's disease Nat. Rev. Drug Discovery 2012, 11 (11) 833-46
143. Nishimura, Y.; Ito, T.; Hoe, K.; Saavedra, J. M. Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist candesartan blocks brain AT(1) receptors Brain Res. 2000, 871 (1) 29-38
144. Noda, A.; Fushiki, H.; Murakami, Y.; Sasaki, H.; Miyoshi, S.; Kakuta, H.; Nishimura, S. Brain penetration of telmisartan, a unique centrally acting angiotensin II type 1 receptor blocker, studied by PET in conscious rhesus macaques Nucl. Med. Biol. 2012, 39 (8) 1232-5
145. Fredriksson, K.; Kalimo, H.; Westergren, I.; Kahrstrom, J.; Johansson, B. B. Blood-brain barrier leakage and brain edema in stroke-prone spontaneously hypertensive rats. Effect of chronic sympathectomy and low protein/high salt diet Acta Neuropathol. 1987, 74 (3) 259-68
146. Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10 (7) 1093-5
147. Kumar, G.; Smith, Q. R.; Hokari, M.; Parepally, J.; Duncan, M. W. Brain uptake, pharmacokinetics, and tissue distribution in the rat of neurotoxic N-butylbenzenesulfonamide Toxicol. Sci. 2007, 97 (2) 253-64
148. Garberg, P.; Ball, M.; Borg, N.; Cecchelli, R.; Fenart, L.; Hurst, R. D.; Lindmark, T.; Mabondzo, A.; Nilsson, J. E.; Raub, T. J.; Stanimirovic, D.; Terasaki, T.; Oberg, J. O.; Osterberg, T. In vitro models for the blood-brain barrier Toxicol. In Vitro 2005, 19 (3) 299-334
149. Begley, D. J. Transport to the brain. In The Blood-Brain Barrier and Drug Delivery to CNS; Begley, D. J.; Bradbury, M. W.; Kreuter, J., Eds.; Dekker: New York, 2000, pp 93-108.
150. Kimelberg, H. K. Water homeostasis in the brain: basic concepts Neuroscience 2004, 129 (4) 851-60
151. Abbott, N. J. Evidence for bulk flow of brain interstitial fluid: significance for physiology and pathology Neurochem. Int. 2004, 45 (4) 545-52
152. Cserr, H. Potassium exchange between cerebrospinal fluid, plasma, and brain Am. J. Physiol. 1965, 209 (6) 1219-26
153. Oshio, K.; Watanabe, H.; Song, Y.; Verkman, A. S.; Manley, G. T. Reduced cerebrospinal fluid production and intracranial pressure in mice lacking choroid plexus water channel Aquaporin-1 FASEB J. 2005, 19 (1) 76-8
154. Martins, A. N.; Ramirez, A.; Solomon, L. S.; Wiese, G. M. The effect of dexamethasone on the rate of formation of cerebrospinal fluid in the monkey J. Neurosurg. 1974, 41 (5) 550-4
155. Artru, A. A. Effects of halothane and fentanyl on the rate of CSF production in dogs Anesth. Analg. 1983, 62 (6) 581-5
156. Oppelt, W. W.; Patlak, C. S.; Rall, D. P. Effect of certain drugs on cerebrospinal fluid production in the dog Am. J. Physiol. 1964, 206 (2) 247-50
157. Harashima, H.; Sawada, Y.; Sugiyama, Y.; Iga, T.; Hanano, M. Analysis of nonlinear tissue distribution of quinidine in rats by physiologically based pharmacokinetics J. Pharmacokinet. Biopharm. 1985, 13 (4) 425-40
158. Linde, R.; Hasselbalch, S. G.; Topp, S.; Paulson, O. B.; Madsen, P. L. Global cerebral blood flow and metabolism during acute hyperketonemia in the awake and anesthetized rat J. Cereb. Blood Flow Metab. 2006, 26 (2) 170-80
159. Sheng, H.; Laskowitz, D. T.; Mackensen, G. B.; Kudo, M.; Pearlstein, R. D.; Warner, D. S. Apolipoprotein E deficiency worsens outcome from global cerebral ischemia in the mouse Stroke 1999, 30 (5) 1118-24
160. Itoh, Y.; Esaki, T.; Cook, M.; Qasba, P.; Shimoji, K.; Alroy, J.; Brady, R. O.; Sokoloff, L.; Moore, D. F. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease J. Neurochem. 2001, 79 (6) 1217-24
161. Jay, T. M.; Lucignani, G.; Crane, A. M.; Jehle, J.; Sokoloff, L. Measurement of local cerebral blood flow with [14C]iodoantipyrine in the mouse J. Cereb. Blood Flow Metab. 1988, 8 (1) 121-9
162. Martins, A. N.; Kobrine, A. I.; Doyle, T. F.; Ramirez, A. Total cerebral blood flow in the monkey measured by hydrogen clearance Stroke 1974, 5 (4) 512-7
163. Kassell, N. F.; Baumann, K. W.; Hitchon, P. W.; Gerk, M. K.; Hill, T. R.; Sokoll, M. D. The effects of high dose mannitol on cerebral blood flow in dogs with normal intracranial pressure Stroke 1982, 13 (1) 59-61
164. Shimada, A.; Hasegawa-Ishii, S. Senescence-accelerated Mice (SAMs) as a Model for Brain Aging and Immunosenescence Aging Dis. 2011, 2 (5) 414-35
165. Aanerud, J.; Borghammer, P.; Chakravarty, M. M.; Vang, K.; Rodell, A. B.; Jonsdottir, K. Y.; Moller, A.; Ashkanian, M.; Vafaee, M. S.; Iversen, P.; Johannsen, P.; Gjedde, A. Brain energy metabolism and blood flow differences in healthy aging J. Cereb. Blood Flow Metab. 2012, 32 (7) 1177-87
166. Farrall, A. J.; Wardlaw, J. M. Blood-brain barrier: ageing and microvascular disease-systematic review and meta-analysis Neurobiol. Aging 2009, 30 (3) 337-352
167. Silverberg, G. D.; Messier, A. A.; Miller, M. C.; Machan, J. T.; Majmudar, S. S.; Stopa, E. G.; Donahue, J. E.; Johanson, C. E. Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging J. Neuropathol. Exp. Neurol. 2010, 69 (10) 1034-43
168. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease Cold Spring Harbor Perspect. Med. 2011, 1 (1) a006189
169. Bartels, A. L.; Kortekaas, R.; Bart, J.; Willemsen, A. T.; de Klerk, O. L.; de Vries, J. J.; van Oostrom, J. C.; Leenders, K. L. Blood-brain barrier P-glycoprotein function decreases in specific brain regions with aging: a possible role in progressive neurodegeneration Neurobiol. Aging 2009, 30 (11) 1818-1824
170. van Assema, D. M.; Lubberink, M.; Boellaard, R.; Schuit, R. C.; Windhorst, A. D.; Scheltens, P.; Lammertsma, A. A.; van Berckel, B. N. P-Glycoprotein Function at the Blood-Brain Barrier: Effects of Age and Gender Mol. Imaging Biol. 2012, 14 (6) 771-6
171. Friedman, A.; Heinemann, U. Role of Blood-Brain Barrier Dysfunction in Epileptogenesis. In Jasper's Basic Mechanisms of the Epilepsies. 4 th ed.; Noebels, J. L.; Avoli, M.; Rogawski, M. A.; Olsen, R. W.; Delgado-Escueta, A. V., Eds.; Oxford University Press: Oxford, 2012; Chapter 27.
172. Appel, S.; Duke, E. S.; Martinez, A. R.; Khan, O. I.; Dustin, I. M.; Reeves-Tyer, P.; Berl, M. B.; Sato, S.; Gaillard, W. D.; Theodore, W. H. Cerebral blood flow and fMRI BOLD auditory language activation in temporal lobe epilepsy Epilepsia 2012, 53 (4) 631-8
173. Bednarczyk, J.; Lukasiuk, K. Tight junctions in neurological diseases Acta Neurobiol. Exp. 2011, 71 (4) 393-408
174. van Vliet, E. A.; da Costa Araújo, S.; Redeker, S.; van Schaik, R.; Aronica, E.; Gorter, J. A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy Brain 2007, 130 (Part 2) 521-34
175. Marchi, N.; Teng, Q.; Ghosh, C.; Fan, Q.; Nguyen, M. T.; Desai, N. K.; Bawa, H.; Rasmussen, P.; Masaryk, T. K.; Janigro, D. Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity Brain Res. 2010, 1353, 176-86
176. Lazarowski, A.; Czornyj, L.; Lubienieki, F.; Girardi, E.; Vazquez, S.; D'Giano, C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy Epilepsia 2007, 48 (Suppl. 5) 140-9
177. Loscher, W.; Potschka, H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs J. Pharmacol. Exp. Ther. 2002, 301 (1) 7-14
178. Dong, L.; Luo, R.; Tong, Y.; Cai, X.; Mao, M.; Yu, D. Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population Brain Res. 2011, 1391, 114-24
179. Awasthi, S.; Hallene, K. L.; Fazio, V.; Singhal, S. S.; Cucullo, L.; Awasthi, Y. C.; Dini, G.; Janigro, D. RLIP76, a non-ABC transporter, and drug resistance in epilepsy BMC Neurosci. 2005, 6, 61
180. Soranzo, N.; Kelly, L.; Martinian, L.; Burley, M. W.; Thom, M.; Sali, A.; Kroetz, D. L.; Goldstein, D. B.; Sisodiya, S. M. Lack of support for a role for RLIP76 (RALBP1) in response to treatment or predisposition to epilepsy Epilepsia 2007, 48 (4) 674-83
181. Ates, N.; Esen, N.; Ilbay, G. Absence epilepsy and regional blood-brain barrier permeability: the effects of pentylenetetrazole-induced convulsions Pharmacol. Res. 1999, 39 (4) 305-10
182. Rizzi, M.; Caccia, S.; Guiso, G.; Richichi, C.; Gorter, J. A.; Aronica, E.; Aliprandi, M.; Bagnati, R.; Fanelli, R.; D'Incalci, M.; Samanin, R.; Vezzani, A. Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance J. Neurosci. 2002, 22 (14) 5833-9
183. van Vliet, E. A.; van Schaik, R.; Edelbroek, P. M.; Voskuyl, R. A.; Redeker, S.; Aronica, E.; Wadman, W. J.; Gorter, J. A. Region-specific overexpression of P-glycoprotein at the blood-brain barrier affects brain uptake of phenytoin in epileptic rats J. Pharmacol. Exp. Ther. 2007, 322 (1) 141-7
184. Marchi, N.; Guiso, G.; Rizzi, M.; Pirker, S.; Novak, K.; Czech, T.; Baumgartner, C.; Janigro, D.; Caccia, S.; Vezzani, A. A pilot study on brain-to-plasma partition of 10,11-dyhydro-10-hydroxy-5H-dibenzo(b,f)azepine-5- carboxamide and MDR1 brain expression in epilepsy patients not responding to oxcarbazepine Epilepsia 2005, 46 (10) 1613-9
185. Friedman, A. Blood-brain barrier dysfunction, status epilepticus, seizures, and epilepsy: a puzzle of a chicken and egg? Epilepsia 2011, 52 (Suppl. 8) 19-20
186. Serrano-Pozo, A.; Frosch, M. P.; Masliah, E.; Hyman, B. T. Neuropathological alterations in Alzheimer disease Cold Spring Harbor Perspect. Med. 2011, 1 (1) a006189
187. Palmer, J. C.; Baig, S.; Kehoe, P. G.; Love, S. Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta Am. J. Pathol. 2009, 175 (1) 262-70
188. Bowman, G. L.; Quinn, J. F. Alzheimer's disease and the Blood-Brain Barrier: Past, Present and Future Aging Health 2008, 4 (1) 47-55
189. Claudio, L. Ultrastructural features of the blood-brain barrier in biopsy tissue from Alzheimer's disease patients Acta Neuropathol. 1996, 91 (1) 6-14
190. Dutheil, F.; Jacob, A.; Dauchy, S.; Beaune, P.; Scherrmann, J.-M.; Declèves, X.; Loriot, M.-A. ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders Expert Opin. Drug Metab. Toxicol. 2010, 6 (10) 1161-74
191. Morley, J. E.; Farr, S. A.; Kumar, V. B.; Armbrecht, H. J. The SAMP8 mouse: a model to develop therapeutic interventions for Alzheimer's disease Curr. Pharm. Des 2012, 18 (8) 1123-30
192. Rapposelli, S.; Digiacomo, M.; Balsamo, A. P-gp transporter and its role in neurodegenerative diseases Curr. Top. Med. Chem. 2009, 9 (2) 209-17
193. Hsu, J. L.; Jung, T. P.; Hsu, C. Y.; Hsu, W. C.; Chen, Y. K.; Duann, J. R.; Wang, H. C.; Makeig, S. Regional CBF changes in Parkinson's disease: a correlation with motor dysfunction Eur. J. Nucl. Med. Mol. Imaging 2007, 34 (9) 1458-66
194. Vautier, S.; Fernandez, C. ABCB1: the role in Parkinson's disease and pharmacokinetics of antiparkinsonian drugs Expert Opin. Drug Metab Toxicol. 2009, 5 (11) 1349-58
195. Westerlund, M.; Belin, A. C.; Olson, L.; Galter, D. Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients Cell Tissue Res. 2008, 334 (2) 179-185
196. Carvey, P. M.; Zhao, C. H.; Hendey, B.; Lum, H.; Trachtenberg, J.; Desai, B. S.; Snyder, J.; Zhu, Y. G.; Ling, Z. D. 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability Eur. J. Neurosci. 2005, 22 (5) 1158-68
197. Bartels, A. L.; Willemsen, A. T.; Kortekaas, R.; de Jong, B. M.; de Vries, R.; de Klerk, O.; van Oostrom, J. C.; Portman, A.; Leenders, K. L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA J. Neural Transm. 2008, 115 (7) 1001-9
198. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P. O. The blood-brain barrier in brain homeostasis and neurological diseases Biochim. Biophys. Acta 2009, 1788 (4) 842-57
199. Ingrisch, M.; Sourbron, S.; Morhard, D.; Ertl-Wagner, B.; Kumpfel, T.; Hohlfeld, R.; Reiser, M.; Glaser, C. Quantification of perfusion and permeability in multiple sclerosis: dynamic contrast-enhanced MRI in 3D at 3T Invest. Radiol. 2012, 47 (4) 252-8
200. Kooij, G.; Backer, R.; Koning, J. J.; Reijerkerk, A.; van Horssen, J.; van der Pol, S. M. A.; Drexhage, J.; Schinkel, A.; Dijkstra, C. D.; den Haan, J. M. M.; Geijtenbeek, T. B. H.; de Vries, H. E. P-glycoprotein acts as an immunomodulator during neuroinflammation PLoS One 2009, 4 (12) e8212